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Abstract
A critical debate in the race to develop, market, and distribute COVID-19 vaccines could define the 
future of this pandemic: How much evidence demonstrating a vaccine’s safety and efficacy should be 
required before it is considered “essential”? If a COVID-19 vaccine were to be designated an essential 
medicine by the World Health Organization, this would invoke special “core” human rights duties for 
governments to provide the vaccine as a matter of priority irrespective of resource constraints. States 
would also have duties to make the vaccine available in adequate amounts, in the appropriate dosage 
forms, with assured quality and adequate information, and at an affordable price. This question is 
especially critical and unique given that COVID-19 vaccines have in many cases been authorized for use 
via national emergency use authorization processes—mechanisms that enable the public to gain access 
to promising medical products before they have received full regulatory approval and licensure. In this 
paper, we examine whether unlicensed COVID-19 vaccines authorized for emergency use should ever 
be considered essential medicines, thereby placing prioritized obligations on countries regarding their 
accessibility and affordability.
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Introduction
A critical debate in the race to develop, market, 
and distribute COVID-19 vaccines could define 
the future of this pandemic: How much evidence 
demonstrating a vaccine’s safety and efficacy 
should be required before it is considered “essen-
tial”? The World Health Organization’s (WHO) 
concept of “essential medicines” suggests that 
COVID-19 vaccines that satisfy priority health care 
needs and have public health relevance, evidence 
on efficacy and safety, and comparative cost-effec-
tiveness should be considered strong candidates 
for being listed as “essential medicines.”1 This is 
important because if a COVID-19 vaccine were to 
be designated an essential medicine by WHO, this 
would invoke special “core” human rights duties 
for governments to provide the vaccine as a matter 
of priority irrespective of resource constraints.2 
States would also have duties to make the vaccine 
available in adequate amounts, in the appropriate 
dosage forms, with assured quality and adequate 
information, and at an affordable price.3
This question is especially critical and unique 
given that COVID-19 vaccines have in many cases 
been authorized for use via national emergency 
use authorization (EUA) processes—mechanisms 
that enable the public to gain access to promising 
medical products before they have received regula-
tory approval and licensure.4 With some countries 
poised to vaccinate their entire populations under 
emergency use authorizations, in addition to many 
other COVID-19 vaccines in the pipeline and the 
potential need for new vaccines to address variants 
of concern, vaccination under EUAs could con-
tinue to be the norm for COVID-19 vaccination 
programs.
Might it be possible for COVID-19 vaccines 
to meet WHO’s standards to be considered an 
essential medicine? Undoubtedly, any COVID-19 
vaccine would satisfy the condition of disease 
prevalence and public health relevance. Whether 
a COVID-19 vaccine is comparatively cost-effec-
tive will depend on the product, its price, and its 
alternatives. Vaccine pricing may invoke legal and 
political challenges regarding intellectual property 
rights well-traversed in relation to other essential 
and non-essential pharmaceuticals over the past 
decades.5 The critical gray area we focus on in this 
paper—and therefore the crux of essentiality in 
this case—is determining the evidentiary standard 
of clinical efficacy and safety that must be met in 
the context of a public health emergency in order 
for a COVID-19 vaccine to be deemed an essential 
medicine. In this paper, we focus specifically on 
whether unlicensed COVID-19 vaccines autho-
rized for emergency use should ever be considered 
essential medicines, thereby placing prioritized ob-
ligations on countries regarding their accessibility 
and affordability. We first outline the implications 
of right to health standards for essential medicines, 
then consider whether EUA COVID-19 vaccines 
should ever be considered as candidates for essen-
tial medicines status, and conclude by evaluating 
WHO’s Emergency Use Listing procedure as a po-
tential mechanism for categorizing emergency use 
vaccines for the purposes of being considered for 
essential medicines status.
Essential medicines and the right to health 
Essential medicines, which include vaccines, hold 
considerable importance in the interpretive frame-
works of the right to health, as they are critical to 
individual and population health. According to ar-
ticle 12 of the International Covenant on Economic, 
Social and Cultural Rights (ICESCR), states have 
obligations to prevent and control epidemics.6 In 
General Comment 14, the Committee on Economic, 
Social and Cultural Rights notes that the provision 
of vaccines is critical to fulfilling this objective.7 The 
committee has also firmly positioned the provision 
of essential medicines defined by WHO as a “core 
obligation” under the right to health. Such obli-
gations are defined in General Comment 3 as the 
minimum standards that must be met by states in 
order to give meaning to the enjoyment of covenant 
rights.8 Core obligations to provide essential med-
icines under the right to health do not necessarily 
constitute a strictly binding (rather than authorita-
tive) legal standard, even for the 171 states that have 
ratified the ICESCR.9 However, national govern-
ments have enshrined the state duty to guarantee 
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access to essential or needed medicines for all in 
various domestic legal frameworks, from binding 
constitutional law and universal health coverage 
laws to national medicines policies guiding the 
pharmaceutical sector.10 For instance, at the height 
of the AIDS crisis, state provision of “essential” 
antiretrovirals as part of the fulfilment of the right 
to health recognized in domestic constitutions 
and international treaties was enforced through 
domestic courts.11 This evidence suggests that core 
obligations hold a customary legal status.
 There is increasing consensus in the inter-
national community of an emerging custom that 
essential medicines should be part of the human 
right to health. For instance, the international 
community has used the human rights language 
of access to medicines to create new global health 
institutions such as the Global Fund to Fight AIDS, 
Tuberculosis and Malaria, which provides free ac-
cess for developing countries that cannot provide 
relevant medicines for their citizens. This seems to 
imply a wider recognition that access to medicines 
should be part of a broader realization of the right 
to health.12
Irrespective of the precise legal status of core 
obligations to provide essential medicines, in a 
global pandemic such as COVID-19, a vaccine’s des-
ignation as an essential medicine by WHO would 
clearly invoke strong and urgent human rights and 
public health responsibilities of states articulated 
in international norms and domestic law, and raise 
fundamental questions about whether states should 
make such products widely available at an afford-
able price.
National emergency use authorizations of 
unlicensed COVID-19 vaccines
The urgent need to alleviate the global crisis caused 
by COVID-19 perhaps necessitates a departure 
from traditional vaccine regulatory pathways, but 
not at the expense of vaccine safety, efficacy, and 
quality.13 Emergency use authorization processes 
(or similar regulatory mechanisms) allow nation-
al regulatory authorities to authorize the use of 
unapproved medical products in a public health 
emergency in order to diagnose, treat, or prevent 
serious or life-threatening diseases or conditions 
when there are no adequate, approved, and avail-
able alternatives, but prior to there being sufficient 
evidence to meet the standards required for regula-
tory approval.14 For example, at the time of writing, 
the US Food and Drug Administration (FDA) had 
issued EUAs for three COVID-19 vaccines, 10 drug 
and biological therapeutic products, and 346 in 
vitro diagnostic products.15 Also of note is that the 
FDA issued EUAs for chloroquine and hydroxy-
chloroquine, which were later revoked following 
the removal of hydroxychloroquine as a COVID-19 
treatment in WHO’s Solidarity Trial.16
Given these national-level authorizations, a 
pertinent question is whether unlicensed medical 
products authorized for emergency use, includ-
ing vaccines, should ever be considered essential 
medicines, thereby placing prioritized obligations 
on countries regarding their accessibility and af-
fordability. On the one hand, this is an attractive 
idea. For example, COVID-19 vaccines that have 
promising safety and efficacy profiles and are 
issued EUAs could be critical to combatting the 
pandemic in a timely manner. Yet, if such vaccines 
are neither accessible nor affordable, then the least 
advantaged will be disproportionately harmed. If 
listing COVID-19 vaccines that have received EUAs 
as essential medicines would trigger responsibili-
ties to make these products available and accessible 
at an affordable price, this could have the potential 
to address the problem of accessibility.17 However, it 
is important to note that human rights obligations 
with respect to essential medicines are not absolute 
and are subject to gradual fulfillment, and so being 
listed as an essential medicine would of course not 
guarantee accessibility. Listing COVID-19 vaccines 
as essential medicines only once they receive mar-
ket licensure—that is, long after they are likely to 
have received EUAs in many countries—means 
that many months may pass in which many people, 
including the least advantaged, are less able to ben-
efit from these vaccines. Proposals exist for the fair 
allocation of unlicensed medical products autho-
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rized for emergency use, but they do not establish 
obligations in the same way that being listed as an 
essential medicine does.18 
While listing an EUA vaccine as “essential” 
would have important advantages, it may seem 
counterintuitive to consider a medical product 
“essential” when evidence for that product has 
not met traditional standards of safety and effica-
cy. There are several reasons that militate against 
considering unlicensed medical products to be 
essential medicines even if there are countries that 
have authorized them for emergency use. First, 
as the US FDA’s issuance and later revocation of 
EUAs of chloroquine and hydroxychloroquine 
for COVID-19 highlights, evidence may quickly 
emerge that a medical product’s safety or efficacy 
profile no longer supports its emergency use. Giv-
en the attenuated evidentiary standards that exist 
for EUAs compared with market licensure, it may 
be too hasty to consider such medicines “essen-
tial.” Second, as the global race for a COVID-19 
vaccine demonstrates, political factors, including 
vaccine nationalism, can have a perverse influence 
on the issuance of EUAs. In other words, vaccine 
nationalism could inappropriately incentivize 
governments to issue EUAs. Given that countries 
have been criticized for hurried approvals of vac-
cine candidates because of concerns over a lack of 
safety and efficacy data, it is hard to imagine how 
such products could at the same time be considered 
“essential.”19 That the US FDA has resisted politi-
cal pressure to abruptly issue EUAs for COVID-19 
vaccines emphasizes the paramount need to ensure 
a high degree of safety and efficacy prior to the 
procurement and widespread dissemination of a 
potentially dangerous vaccine by a government to 
its population.20
There are also several potentially negative 
implications of listing EUA COVID-19 vaccines as 
essential medicines. Namely, labeling such prod-
ucts “essential” could create the impression that the 
safety and efficacy of such products is more certain 
than it actually is. One can only imagine the con-
sequences had chloroquine or hydroxychloroquine 
been deemed “essential medicines” for COVID-19 
when they received EUAs in the United States. In 
addition, considering such medical products as es-
sential medicines candidates could have profound 
and far-reaching effects on the perceived value of 
investigational medical products more generally, 
such as by emboldening “right to try” movements 
for medical products whose clinical value and safety 
is unknown.21 Finally, recognizing an EUA product 
as “essential” would trigger the obligation on states 
to provide it affordably to all. Consider in this 
scenario the potential for states to pour significant 
investments into “essential” EUA products of ques-
tionable added value for diagnosing, preventing, or 
treating COVID-19. Worse yet would be the oppor-
tunity costs if those investments precluded a state’s 
future purchase of other COVID-19 products that 
are proven resolutely safe and effective. For exam-
ple, because of the FDA’s issuance and subsequent 
revocation of an EUA for hydroxychloroquine, the 
US federal government was left with a stockpile 
of 63 million doses of a drug that is ineffective in 
treating COVID-19 and whose cost could have been 
spent elsewhere.22
These arguments suggest that the mere fact 
that a COVID-19 vaccine has received emergency 
authorization should not automatically render it a 
candidate for essential medicine status. Conversely, 
in a public health crisis, it may seem imprudent to 
require that COVID-19 vaccines receive licensure 
before they can be considered essential medicines, 
particularly if vaccination programs are likely to 
continue under EUAs for some time. Given the dire 
need for COVID-19 vaccines and the real prospect 
that the least advantaged will not have the oppor-
tunity to access or afford them if and when they are 
authorized for emergency use, a middle ground is 
needed.
WHO’s Emergency Use Listing procedure
A potential middle ground would be to leverage the 
WHO Emergency Use Listing procedure, a risk-
based procedure for assessing and expediting the 
listing of unlicensed diagnostics, therapeutics, and 
vaccines for use during public health emergencies.23 
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At the time of writing, three COVID-19 vaccines 
had been issued emergency use validation through 
this process.24
Utilizing this procedure would have the 
benefit of considering (but not guaranteeing) es-
sential medicine status only among those medical 
products that have undergone a global, systematic, 
consistent, transparent, and coordinated process 
for assessing and listing medical products for 
emergency use. Relying on a global process with 
harmonized standards could help identify vaccines 
that should be considered for essential medicine 
status without the risks associated with national 
EUAs. COVID-19 vaccines that have been listed via 
WHO’s Emergency Use Listing procedure could 
therefore serve as the authoritative roster of medi-
cines authorized for emergency use that WHO may 
further independently consider for the purposes of 
being listed as essential medicines.
Conclusion
Given the lower evidentiary standards for EUAs 
relative to market licensure, political factors that 
can influence the issuance of EUAs, and the possi-
bility that labeling such products “essential” could 
create the impression that the safety and efficacy 
of such products is more certain than it actually 
is, COVID-19 vaccines authorized for emergency 
use should not automatically be considered as can-
didates for essential medicine status. Yet, in the 
context of a pandemic and large-scale vaccination 
programs rolled out under EUAs (or similar regu-
latory mechanisms), it may be imprudent to require 
that COVID-19 vaccines wait to receive licensure 
before they can be considered as essential medi-
cines. We therefore argue that COVID-19 vaccines 
authorized for emergency use should not necessar-
ily be precluded from being considered as essential 
medicines candidates, but rather be considered 
for essential medicine status only if they have un-
dergone a systematic, consistent, transparent, and 
coordinated process for being assessed and listed 
for emergency use. WHO’s Emergency Use Listing 
procedure comprises harmonized standards and 
can serve as an authoritative roster of vaccines that 
may be further independently considered for essen-
tial medicines status.
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